Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Valion Bio, Inc.TIVC · Entity 8459 | Chief Operating Officer | May 08, 2023 | May 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Valion Bio, Inc.
Report date May 08, 2023 · Filed May 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.13 · Expires 2033-05-07 | Direct | 100,000 |
Reported balance
After 2023-05-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-08 · Grant · Acquired 100,000 · Balance 100,000 F1: The option vests as follows: (i) 25% one year from the grant date, and (ii) the remaining 75% in equal monthly installments over the 36 months thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as follows: (i) 25% one year from the grant date, and (ii) the remaining 75% in equal monthly installments over the 36 months thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2023 Filed May 10, 2023 22:44 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0000899243-23-012534 · doc4.xml · derivative · entry 1 Sabia Ryan · CIK 0001892415 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-05-07 F1 · derivative.exercise_date: The option vests as follows: (i) 25% one year from the grant date, and (ii) the remaining 75% in equal monthly installments over the 36 months thereafter. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 22:35 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001104659-22-014171 · tm225821d3_4.xml · derivative · entry 1 Sabia Ryan · CIK 0001892415 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-02-03 F1 · derivative.exercise_date: The option vests as follows: (i) 25% one year from the grant date, and (ii) the remaining 75% in equal monthly installments over the next 36 months. Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 01:37 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-21-150712 · tm2135733d2_4.xml · derivative · entry 1 Sabia Ryan · CIK 0001892415 · VP of Sales and Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-13 F1 · derivative.exercise_date: The option vests as follows: (i) 25% one year from the grant date, and (ii) the remaining 75% in equal monthly installments over the next 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.